Enhertu Snub From England’s NICE Not ‘In Line’ With Other Countries

 
• By Eliza Slawther

England’s NICE has “misclassified” HER2-low metastatic breast cancer as a medium severity disease, say AstraZeneca and Daiichi Sankyo, the co-developers of Enhertu. NICE said it would consider a rapid re-appraisal if the companies offered a “fair price” for the drug.

Outlier
NICE's decision on Enhertu is different from that of many other countries • Source: Shutterstock

More from Market Access

More from Pink Sheet